dalteparin has been researched along with Angina Pectoris in 25 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| " It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors." | 2.71 | Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. ( Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004) |
| "More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9." | 2.71 | Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. ( Antman, EM; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Califf, RM; Cohen, M; Col, J; Ferguson, JJ; Frey, MJ; Fry, E; Goodman, S; Grines, CL; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kereiakes, DJ; Kleiman, NS; Langer, A; Leon, MB; Lopez-Sendon, JL; Mahaffey, KW; Nessel, CC; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H, 2004) |
| " There was no difference in the frequency or severity of adverse events." | 2.70 | A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial). ( Bhargava, VK; Grover, A; Malhotra, S; Pandhi, P; Sharma, YP, 2001) |
| "This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether the ACT or aPTT can be used to monitor intravenous (IV) low molecular weight heparin (LMWH)." | 1.33 | The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. ( Cavusoglu, E; Lakhani, M; Marmur, JD, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 17 (68.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Melandri, G | 1 |
| Semprini, F | 1 |
| Cervi, V | 1 |
| Candiotti, N | 1 |
| Palazzini, E | 1 |
| Branzi, A | 1 |
| Magnani, B | 1 |
| Romero-Castro, MJ | 1 |
| Seoane-García, T | 1 |
| Chaparro-Muñoz, M | 1 |
| García-Borbolla, R | 1 |
| García-Rubira, JC | 1 |
| Martí, V | 1 |
| García-Picart, J | 1 |
| Carballeira, L | 1 |
| Cannon, CP | 1 |
| Knight, D | 1 |
| Genest, M | 1 |
| Pochmalicki, G | 1 |
| Blazing, MA | 2 |
| de Lemos, JA | 2 |
| White, HD | 1 |
| Fox, KA | 2 |
| Verheugt, FW | 1 |
| Ardissino, D | 1 |
| DiBattiste, PM | 1 |
| Palmisano, J | 1 |
| Bilheimer, DW | 1 |
| Snapinn, SM | 1 |
| Ramsey, KE | 1 |
| Gardner, LH | 1 |
| Hasselblad, V | 2 |
| Pfeffer, MA | 1 |
| Lewis, EF | 1 |
| Braunwald, E | 2 |
| Califf, RM | 3 |
| Ferguson, JJ | 2 |
| Antman, EM | 3 |
| Cohen, M | 2 |
| Grines, CL | 2 |
| Goodman, S | 1 |
| Kereiakes, DJ | 1 |
| Langer, A | 2 |
| Mahaffey, KW | 2 |
| Nessel, CC | 2 |
| Armstrong, PW | 1 |
| Avezum, A | 1 |
| Aylward, P | 1 |
| Becker, RC | 1 |
| Biasucci, L | 1 |
| Borzak, S | 1 |
| Col, J | 1 |
| Frey, MJ | 1 |
| Fry, E | 1 |
| Gulba, DC | 1 |
| Guneri, S | 1 |
| Gurfinkel, E | 1 |
| Harrington, R | 1 |
| Hochman, JS | 1 |
| Kleiman, NS | 1 |
| Leon, MB | 1 |
| Lopez-Sendon, JL | 1 |
| Pepine, CJ | 1 |
| Ruzyllo, W | 1 |
| Steinhubl, SR | 1 |
| Teirstein, PS | 1 |
| Toro-Figueroa, L | 1 |
| White, H | 1 |
| Petersen, JL | 1 |
| Goodman, SG | 1 |
| Le-Moigne-Amrani, A | 1 |
| Harrington, RA | 1 |
| Das, P | 1 |
| Moliterno, DJ | 1 |
| Smith, LA | 1 |
| Harkness, M | 1 |
| Kanna, B | 1 |
| Sharma, P | 1 |
| Pedrini, M | 1 |
| Hartig, F | 1 |
| Pechlaner, C | 1 |
| Cavusoglu, E | 1 |
| Lakhani, M | 1 |
| Marmur, JD | 1 |
| Boztosun, B | 1 |
| Gunes, Y | 1 |
| Kirma, C | 1 |
| Barutcu, I | 1 |
| Aydin, Y | 1 |
| Ozçakar, L | 1 |
| Ustün, I | 1 |
| Aydin, LY | 1 |
| Bassand, JP | 1 |
| Mehta, SR | 1 |
| Wallentin, L | 1 |
| Theroux, P | 1 |
| Piegas, LS | 1 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Yusuf, S | 1 |
| Fujita, M | 1 |
| Sasayama, S | 1 |
| Kato, K | 1 |
| Takaori, S | 1 |
| Glick, A | 1 |
| Kornowski, R | 1 |
| Michowich, Y | 1 |
| Koifman, B | 1 |
| Roth, A | 1 |
| Laniado, S | 1 |
| Keren, G | 1 |
| Stone, GW | 1 |
| Rabah, MM | 1 |
| Premmereur, J | 1 |
| Graham, M | 1 |
| Fareed, J | 1 |
| Hoppensteadt, DA | 1 |
| Grines, LL | 1 |
| Gurfinkel, EP | 1 |
| Santopinto, J | 1 |
| Bozovich, GE | 1 |
| Quispe, A | 1 |
| Strinna, A | 1 |
| Mautner, B | 1 |
| Malhotra, S | 1 |
| Bhargava, VK | 1 |
| Grover, A | 1 |
| Pandhi, P | 1 |
| Sharma, YP | 1 |
| Henry, TD | 1 |
| Satran, D | 1 |
| Knox, LL | 1 |
| Iacarella, CL | 1 |
| Laxson, DD | 1 |
| Preisack, MB | 1 |
| Bonan, R | 1 |
| Meisner, C | 1 |
| Eschenfelder, V | 1 |
| Karsch, KR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dalteparin and Angina Pectoris
| Article | Year |
|---|---|
[Acute coronary syndromes without ST segment elevation].
Topics: Acute Disease; Adrenergic beta-Antagonists; Analgesics, Opioid; Angina Pectoris; Angiotensin-Convert | 2004 |
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Topics: Angina Pectoris; Angina, Unstable; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa | 2004 |
10 trials available for dalteparin and Angina Pectoris
| Article | Year |
|---|---|
Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Angina Pectoris; Bleeding Time; Cardiovascular Agents; Double-Blind Method; Drug Therap | 1993 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans | 2004 |
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrinolytic Agents; Hemo | 2004 |
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac; | 2007 |
Prospective, randomized, placebo-controlled, double-blind, multicenter study of exercise with enoxaparin pretreatment for stable-effort angina.
Topics: Adult; Aged; Angina Pectoris; Cineangiography; Collateral Circulation; Double-Blind Method; Electroc | 1995 |
Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Enoxaparin; Female; Fibrinolytic Ag | 1996 |
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxa | 1999 |
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Fema | 2000 |
A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial).
Topics: Adult; Aged; Angina Pectoris; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Female; Heparin; Hu | 2001 |
Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial).
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Female; Heparin; | 1998 |
13 other studies available for dalteparin and Angina Pectoris
| Article | Year |
|---|---|
A 70-Year-Old Woman With a Prosthetic Mitral Valve and Sudden Chest Pain.
Topics: Aged; Angina Pectoris; Coronary Thrombosis; Enoxaparin; Female; Fibrinolytic Agents; Graft Occlusion | 2018 |
[Acute coronary syndrome due to distal embolization of a thrombus located in the left main coronary artery].
Topics: Acute Coronary Syndrome; Angina Pectoris; Angiography; Anticoagulants; Coronary Thrombosis; Electroc | 2011 |
Evidence-based risk stratification to target therapies in acute coronary syndromes.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Co | 2002 |
Which heparin is best. When cardiac catheterization is needed, know your heparins.
Topics: Angina Pectoris; Anticoagulants; Cardiac Catheterization; Contraindications; Enoxaparin; Humans; Mal | 2003 |
Fractionating heparins and their clinical trial data--something for everyone.
Topics: Angina Pectoris; Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infa | 2004 |
A case of two adverse reactions.
Topics: Aged; Anaphylaxis; Angina Pectoris; Angioedema; Anticoagulants; Coronary Stenosis; Drug Interactions | 2004 |
Enoxaparin vs unfractionated heparin in acute coronary syndrome.
Topics: Angina Pectoris; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 2004 |
Enoxaparin vs unfractionated heparin in acute coronary syndrome.
Topics: Angina Pectoris; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 2004 |
The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Topics: Angina Pectoris; Anticoagulants; Blood Coagulation; Cardiac Catheterization; Coronary Angiography; D | 2005 |
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinatio | 2006 |
A salient rectus abdominis hematoma due to enoxaparin.
Topics: Abdominal Pain; Aged; Angina Pectoris; Anticoagulants; Diagnosis, Differential; Enoxaparin; Hematoma | 2007 |
Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
Topics: Abciximab; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Topics: Angina Pectoris; Anticoagulants; Blood Coagulation; Cardiac Catheterization; Dose-Response Relations | 2001 |